Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. September 2017 17:27 ET | Quelle: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer

Company Release no. 19/2017 To: NASDAQ Copenhagen A/S ...
12. September 2017 00:00 ET | Quelle: Veloxis Pharmaceuticals A/S

Veloxis Increases Share Capital in Connection with Exercise of Warrants

Company Announcement no. 18/2017 To: NASDAQ Copenhagen...
16. August 2017 11:13 ET | Quelle: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017

Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017 Highlights Revenue reached tUSD 16,168 in the first half of 2017 representing an...
03. Juli 2017 14:00 ET | Quelle: Veloxis Pharmaceuticals A/S

Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 June 2017

Company Release no. 16/2017 To: NASDAQ Copenhagen A/S ...
21. Juni 2017 17:00 ET | Quelle: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program

Company Release no. 15/2017 To: NASDAQ Copenhagen A/S ...
14. Juni 2017 23:00 ET | Quelle: Veloxis Pharmaceuticals A/S

Veloxis Increases Share Capital in Connection with Exercise of Warrants

Company Release no. 14/2017 To: NASDAQ Copenhagen...
05. Juni 2017 20:38 ET | Quelle: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S Announces Agreement with Chiesi Farmaceutici S.p.A. to Commercialize Envarsus XR in China

Company Release no. 13/2017 To: NASDAQ Copenhagen A/S ...
05. Juni 2017 02:55 ET | Quelle: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Envarsus XR® in Canada

Investor News no. 04/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 05 June...
16. Mai 2017 11:21 ET | Quelle: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2017

Highlights It is now estimated that over 6,000 patients in the US and Europe are being treated with Envarsus XR. In the US, prescription growth of Envarsus in the first quarter...
29. April 2017 18:00 ET | Quelle: Veloxis Pharmaceuticals A/S

Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 April 2017

Company Release no. 11/2017 To: NASDAQ Copenhagen...

Vorherige Seite

Nächste Seite